Abstract: A method of joining first and second blade components of a rotor blade of a wind turbine includes providing corresponding first and second positioning elements at an interface of the first and second blade components. The method also includes aligning and securing the first positioning element of the first blade component with the second positioning element of the second blade component so as to temporarily secure the first and second blade components together. Further, the corresponding first and second positioning elements maintain a desired spacing between the first and second blade components. Moreover, the method includes permanently securing the first and second blade components together such that the desired spacing is maintained between the first and second blade components.

Abstract: A garment security hanger and display comprising one or more hanger assemblies, one or more lock rod assemblies, and a base. Each hanger assembly comprises a hanger body with an integral locking device and indicator mechanism. The present invention provides for the placement of a garment on a hanger assembly before the hanger assembly is releasably attached to a lock rod assembly. The lock rod assembly is typically inserted through a sleeve of the garment before being inserted into a channel formed in the hanger assembly. When the lock rod assembly is fully inserted into the channel, the locking device is engaged and the indicator flags the locked status. The hanger assembly may be unlocked by a key inserted in the locking device, allowing the lock rod assembly to be extracted. The present invention possesses a simple, yet scalable, design for economical manufacture and widespread retail use.

Abstract: A garment security hanger and display comprising one or more hanger assemblies, one or more lock rod assemblies, and a base. Each hanger assembly comprises a hanger body with an integral locking device and indicator mechanism. The present invention provides for the placement of a garment on a hanger assembly before the hanger assembly is releasably attached to a lock rod assembly. The lock rod assembly is typically inserted through a sleeve of the garment before being inserted into a channel formed in the hanger assembly. When the lock rod assembly is fully inserted into the channel, the locking device is engaged and the indicator flags the locked status. The hanger assembly may be unlocked by a key inserted in the locking device, allowing the lock rod assembly to be extracted. The present invention possesses a simple, yet scalable, design for economical manufacture and widespread retail use.

Abstract: A unitary boot-type ankle brace is provided having the capability of stabilizing an ankle against inversion and eversion without limiting normal plantarflexion and dorsiflexion of the ankle and while simultaneously providing focal compression of the anterior talofibular ligament. The brace is preferably constructed of a flexible material and includes a medial side portion dimensioned and configured to extend along a medial side of a user's leg and foot, and having a lateral side portion dimensioned and configured to extend along a lateral side of the leg and foot. The side portions are joined to a forwardly extending forefoot sleeve portion and to a base portion. In a primary aspect of the invention the side portions define a rear opening for insertion of the foot with a strap for selectively connecting the side portions adjacent the user's heel.

Abstract: This invention pertains to a new type of ruler for measuring the angle of inclination of a portion of terrain from a topographical map. Topographical maps contain precise information relating to elevation changes and distances. These two pieces of information can be used together to devise a scale to measure the angle of inclination, or pitch, of any slope represented on the map. The invention is simply the inscription of such a scale on a straight, flat material. The invention can be made with a unique scale for any given map scale and contour interval height.

Abstract: Peptides comprising, in sequence, units selected from the amino acid residues 17 to 24 of VIP, and consisting at least of the amino acid residues 18 to 23, or an analogue thereof wherein one or more of the amino acid residues is replaced by an equivalent other amino acid; having anti-ulcer activity, a process for their preparation and their use as pharmaceuticals.

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof:Ar--CO--X--Y--Z--OR.sub.1 (I)wherein: Ar is a group of formula (a): ##STR1## wherein either R.sub.2 is C.sub.1-6 alkoxy and one of R.sub.3, R.sub.4 and R.sub.5 is hydrogen and the other two are selected from hydrogen, halogen, CF.sub.3, CX.sub.1-6 alkylthio, C.sub.1-7 acyl, C.sub.1-6 alkoxy, C.sub.1-10 carboxylic acylamino, C.sub.1-6 alkyl S(O)n wherein n is 1 or 2, nitro or amino, aminocarbonyl or aminosulphonyl optionally substituted by one or two groups selected from C.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, C.sub.3-8 cycloalkyl C.sub.1-4 alkyl or phenyl C.sub.1-4 alkyl groups any of which phenyl moieties may be substituted by one or two groups selected from halogen, CF.sub.3, C.sub.1-6 alkyl or C.sub.1-6 alkoxy; or R.sub.2 is hydrogen and R.sub.3, R.sub.4 and R.sub.5 are independently selected from hydrogen, C.sub.1-6 alkyl, hydroxy, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio or halo; or any two on adjacent carbon atoms together are C.sub.

Abstract: Compounds of formula (i) and pharmaceutically acceptable salts thereof: ##STR1## wherein: m and n are independently 1 or 2 and p is 0, 1 or 2 such that m+n+p.gtoreq.3;R.sub.1 and R.sub.2 are independently hydrogen, C.sub.1-6 alkyl, phenyl or phenyl-C.sub.1-6 alkyl, which phenyl moieties may be substituted by C.sub.1-6 alkyl, C.sub.1-6 alkoxy or halogen;Ar is a group of formula (a): ##STR2## wherein either R.sub.3 is hydrogen or C.sub.1-7 alkanoyl; and X is chloro, bromo, methylthio or nitro; having gastric motility enhancing activity, anti-emetic activity and/or 5-HT antagonist activity, a process for their preparation, and their use as pharmaceuticals.

Abstract: Peptides comprising, in sequence, units selected from the amino acid residues 11 to 23 of vasoactive intestinal peptide (VIP) and consisting at least of the amino acid residues 15 to 20, or an analogue thereof wherein one or more of the amino acid residues is replaced by an equivalent other amino acid, or a pharmaceutically acceptable salt thereof; having pharmacological activity, a process for their preparation and their use as pharmaceuticals.

Abstract: Compounds of formula (I): ##STR1## wherein: one of X and Y is CO and the other is NH;R.sub.1 is C.sub.1-6 alkoxy or C.sub.1-6 alkylthio;R.sub.2 is hydrogen, trifluoromethyl, C.sub.1-6 alkylthio, C.sub.1-7 acyl, C.sub.1-7 acylamino, C.sub.1-6 alkylsulphonyl, C.sub.1-6 alkylsulphinyl, halogen, nitro or amino, aminocarbonyl or aminosulphonyl optionally N-substituted by one or two groups selected from C.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, C.sub.3-8 cycloalkyl C.sub.1-4 alkyl, phenyl or phenyl C.sub.1-4 alkyl groups any of which phenyl moieties may be substituted by one or more halogen, trifluoromethyl, C.sub.1-6 alkoxy or nitro groups, or N-disubstituted by C.sub.2-5 polymethylene;R.sub.3 is amino, aminocarbonyl or aminosulphonyl N-substituted by one or two C.sub.3-8 cycloalkyl, C.sub.3-8 cycloalkyl C.sub.1-4 alkyl, phenyl or phenyl C.sub.1-4 alkyl groups any of which phenyl moieties may be substituted by one or more halogen, trifluoromethyl, C.sub.1-6 alkoxy or nitro groups, or N-disubstituted by C.sub.

Abstract: Compounds of formula (I), pharmaceutically acceptable salts, quaternary derivatives and N-oxides thereof, and pharmaceutically acceptable solvates of any of the foregoing: ##STR1## wherein p is 1 to 3;B is C.sub.1-7 alkyl, C.sub.3-8 cycloalkyl, C.sub.3-8 cycloalkyl-C.sub.1-2 alkyl, or a group (CH.sub.2).sub.t R.sub.11 where t is 1 or 2 and R.sub.11 is thienyl or furyl optionally substituted or is phenyl optionally substituted; and(i) A is a group of formula (II): ##STR2## in which either (a) one of X and Y is CO and the other is NH; or X is CO and Y is NR.sub.6 ; and or(b) one of X and Y is CO and the other is NH; or(ii) A is a group of formula (III): ##STR3## in which one of X and Y is CO and the other is NH, having useful pharmacological properties, pharmaceutical compositions containing them, a process and intermediates for their preparation, and the use of the compounds.

Abstract: Pharmaceutical compositions comprising compounds of formula (I) or pharmaceutically acceptable salts and/or N-oxides and/or solvates thereof: ##STR1## wherein: R.sub.1 is a C.sub.1-6 alkoxy or C.sub.1-6 alkylthio group; andone of R.sub.2, R.sub.3 and R.sub.4 is hydrogen, the second is C.sub.1-6 alkylthio and the third is selected from the class of substituents consisting of hydrogen, halogen, CF.sub.3, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio, C.sub.1-7 acyl, C.sub.1-7 acylamino, C.sub.1-6 alkylsulphonyl, C.sub.1-6 alkylsulphinyl, hydroxy, nitro or amino, aminocarbonyl or aminosulphonyl optionally N-substituted by one or two C.sub.1-6 alkyl groups; orR.sub.1 is joined to R.sub.2 to form C.sub.1-2 alkylenedioxy; andone of R.sub.3 and R.sub.4 is C.sub.1-6 alkylthio and the other is selected from the class of substituents defined above;R.sub.5 is hydrogen or C.sub.1-6 alkyl;R.sub.6 is C.sub.1-7 alkyl or a group --(CH.sub.2).sub.s R.sub.7 where s is 0 to 2 and R.sub.7 is a C.sub.

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof: ##STR1## wherein: n, p and q independently are 0 to 2;R.sub.5 is hydrogen or C.sub.1-6 alkyl;R.sub.6 is C.sub.1-7 alkyl or a group --(CH.sub.2).sub.s R.sub.7 where s is 0 to 2 and R.sub.7 is a C.sub.3-8 cycloalkyl group, or a group --(CH.sub.2).sub.t R.sub.8 where t is 1 or 2 and R.sub.8 is C.sub.2-5 alkenyl or a phenyl group optionally substituted by one or two substituents selected from C.sub.1-6 alkyl, C.sub.1-4 alkoxy, trifluoromethyl and halogen, or a thienyl group;R.sub.12 is C.sub.1-6 alkylsulphonyl;and eitherR.sub.1 is C.sub.1-6 alkoxy or C.sub.1-6 alkylthio; and one of R.sub.2 and R.sub.11 is hydrogen and the other is C.sub.1-6 alkoxy, C.sub.1-6 alkyl or hydroxy; or R.sub.1 and R.sub.2 together are C.sub.1-3 alkylenedioxy; and R.sub.11 is hydrogen, halogen, CF.sub.3, C.sub.1-6 alkoxy,hydroxy, nitro, C.sub.1-7 acyl, amino, C.sub.1-7 acylamino, aminocarbonyl optionally substituted by one or two C.sub.1-6 alkyl, C.sub.